The U.S. District Court for the District of Columbia should vacate the 2022 outpatient prospective payment system rule insofar as it sets a payment rate for 340B hospitals that is lower than the generally applicable payment rate of Average Sales Price plus 6%, AHA told the court yesterday. 

The U.S. Supreme Court in June unanimously ruled in favor of AHA, concluding that HHS鈥 2018 and 2019 reimbursement rates for 340B hospitals were unlawful, but left it to the lower court to determine the appropriate remedy. 

The Court should not give HHS 鈥減ermission to continue violating the law, each and every day, for the remainder of 2022,鈥 AHA wrote. 鈥淗ere, there is only one way for the government to stop violating the law going forward because the rationale of the Supreme Court鈥檚 ruling dictates what HHS must do to fix its violation: reimburse 340B hospitals at the same rate as non-340B hospitals for the remainder of 2022.鈥

Related News Articles

Headline
A U.S. District Court for the District of Columbia judge June 27 ruled against Johnson & Johnson and sided with the Department of Health and Human Services鈥
Headline
The AHA June 16 released a report showing hospitals that participated in the 340B Drug Pricing Program are not only subject to disproportionately greater鈥
Chairperson's File
Public
Advocacy is such an important part of what we do as hospitals and health systems 鈥 and what the AHA does on behalf of our field 鈥 to help ensure that we get鈥
Headline
The AHA June 4 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee in defense of the state鈥檚 340B contract pharmacy law鈥
Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B 鈥渞ebate鈥
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state鈥檚 340B contract pharmacy law鈥